These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36794863)

  • 1. Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies.
    Thai S; Zhuo J; Zhong Y; Xia Q; Chen X; Bao Y; Dhanda D; Priya L; Wu JJ
    J Dermatolog Treat; 2023 Dec; 34(1):2176708. PubMed ID: 36794863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study.
    Tada Y; Kim H; Spanopoulos D; Habiro K; Tsuritani K; Yamada Y; Mandal A; Zhong Y; Hikichi Y
    J Dermatol; 2022 Nov; 49(11):1106-1117. PubMed ID: 35946343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    J Comp Eff Res; 2020 Aug; 9(11):767-779. PubMed ID: 32638609
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis.
    Wu JJ; Pelletier C; Ung B; Tian M
    Curr Med Res Opin; 2020 Jan; 36(1):169-176. PubMed ID: 31517542
    [No Abstract]   [Full Text] [Related]  

  • 7. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.
    Doshi JA; Takeshita J; Pinto L; Li P; Yu X; Rao P; Viswanathan HN; Gelfand JM
    J Am Acad Dermatol; 2016 Jun; 74(6):1057-1065.e4. PubMed ID: 26946986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suboptimal Clinical and Quality of Life Outcomes in Patients with Psoriasis Undertreated with Oral Therapies: International Physician and Patient Survey.
    Thai S; Barlow S; Lucas J; Piercy J; Zhong Y; Zhuo J; Wu JJ
    Dermatol Ther (Heidelb); 2023 Jun; 13(6):1289-1303. PubMed ID: 37253874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
    Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour T; Kern S; Lew C; Zimmerman N; Murage M
    Clin Drug Investig; 2023 Mar; 43(3):185-196. PubMed ID: 36840815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
    Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
    Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
    Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
    J Comp Eff Res; 2019 Jan; 8(1):45-54. PubMed ID: 30387367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis.
    Kaplan DL; Ung BL; Pelletier C; Udeze C; Khilfeh I; Tian M
    Clinicoecon Outcomes Res; 2020; 12():369-377. PubMed ID: 32765022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost of biologic treatment persistence or switching in rheumatoid arthritis.
    Gu T; Mutebi A; Stolshek BS; Tan H
    Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP338-SP345. PubMed ID: 30020745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.
    Sruamsiri R; Iwasaki K; Tang W; Mahlich J
    BMC Dermatol; 2018 Jul; 18(1):5. PubMed ID: 29996929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment.
    Wu JJ; Lu M; Veverka KA; Smulders M; Papademetriou E; Yu J; Feldman SR
    J Dermatolog Treat; 2019 Aug; 30(5):446-453. PubMed ID: 30554541
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis.
    Armstrong A; Xia Q; John AR; Patel V; Seigel L
    Dermatol Ther (Heidelb); 2022 Sep; 12(9):2087-2103. PubMed ID: 35947341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Survival of Biological Therapies for Psoriasis Treatment in Germany and Associated Costs: A Retrospective Claims Database Analysis.
    Mahlich J; Alba A; Hadad LE; Leisten MK; Peitsch WK
    Adv Ther; 2019 Jul; 36(7):1684-1699. PubMed ID: 31102203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis.
    Palmer JB; Li Y; Herrera V; Liao M; Tran M; Ozturk ZE
    BMC Musculoskelet Disord; 2016 Jun; 17():261. PubMed ID: 27301458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
    Corral M; DeYoung K; Kong AM
    BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.